

**BIOCON GROUP**

**FACT SHEET**

**June - 2019**

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		
	<b>(Rs Cr)</b>	
	<b>June 30, 2019</b>	<b>March 31, 2019</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	4,269	4,253
(b) Capital work-in-progress	1,501	1,287
(c) Right-of-use assets	45	-
(d) Goodwill	26	26
(e) Other intangible assets	187	192
(f) Intangible assets under development	669	612
(g) Investments in associates and a joint venture	35	43
(h) Financial assets		
Investments	102	139
Derivative assets	82	71
Other financial assets	40	39
(i) Income-tax asset, net	176	169
(j) Deferred tax asset, net	333	325
(k) Other non-current assets	269	213
	<b>7,735</b>	<b>7,370</b>
<b>Current assets</b>		
(a) Inventories	1,187	1,032
(b) Financial assets		
Investments	665	829
Trade receivables	1,149	1,292
Cash and cash equivalents	773	730
Other bank balances	286	327
Derivative assets	82	78
Other financial assets	584	387
(c) Other current assets	175	149
	<b>4,901</b>	<b>4,823</b>
<b>TOTAL</b>	<b>12,636</b>	<b>12,192</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	300
(b) Other equity	5,664	5,798
<b>Equity attributable to owners of the Company</b>	<b>6,264</b>	<b>6,098</b>
Non-controlling interests	625	609
	<b>6,888</b>	<b>6,707</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	1,634	1,542
Derivative liability	56	35
Other financial liabilities	-	-
(b) Provisions	69	66
(c) Other non-current liabilities	852	805
	<b>2,611</b>	<b>2,448</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	265	261
Trade payables	1,278	1,198
Derivative liability	8	14
Other financial liabilities	1,004	991
(b) Provisions	101	81
(c) Income tax liability, net	169	124
(d) Other current liabilities	311	369
	<b>3,137</b>	<b>3,038</b>
<b>TOTAL</b>	<b>12,636</b>	<b>12,192</b>

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q1 FY 20	Q1 FY 19	Variance
<b>INCOME</b>			
Small molecules	480	400	20%
Biologics	490	250	96%
Branded formulations	133	147	-9%
Research services	421	406	4%
Inter-segment	(58)	(79)	-27%
<b>Revenue from operations #</b>	<b>1,466</b>	<b>1,124</b>	<b>30%</b>
Other income	24	69	-65%
<b>TOTAL REVENUE</b>	<b>1,490</b>	<b>1,193</b>	<b>25%</b>
<b>EXPENDITURE</b>			
Material & Power costs	491	491	0%
Staff costs	309	237	31%
Research & Development expenses*	79	44	78%
Other expenses	149	114	31%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,028</b>	<b>886</b>	<b>16%</b>
<b>EBITDA</b>	<b>462</b>	<b>307</b>	<b>51%</b>
Interest & Finance charges	17	18	-6%
Depreciation & Amortisation	124	99	25%
Share of profit in JV / Associate, net	8	(1)	-1680%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>313</b>	<b>191</b>	<b>64%</b>
Exceptional item, Net	-	-	-
<b>PBT</b>	<b>313</b>	<b>191</b>	<b>64%</b>
Taxes	69	52	32%
Taxes on exceptional item	17	-	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>228</b>	<b>139</b>	<b>65%</b>
Minority interest	21	19	15%
<b>NET PROFIT FOR THE PERIOD</b>	<b>206</b>	<b>120</b>	<b>72%</b>
<b>EPS Rs.</b>	<b>1.7</b>	<b>1.0</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>223</b>	<b>120</b>	<b>86%</b>
Exceptional item, net of taxes	(17)	-	
<b>NET PROFIT FOR THE PERIOD</b>	<b>206</b>	<b>120</b>	<b>72%</b>
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	5	
* Gross Research & Development expenses	110	88	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
Particulars	Q1 FY 20	Q4 FY 19	Variance
<b>INCOME</b>			
Small molecules	480	472	2%
Biologics	490	451	9%
Branded formulations	133	133	0%
Research services	421	534	-21%
Inter-segment	(58)	(61)	-6%
<b>Revenue from operations #</b>	<b>1,466</b>	<b>1,529</b>	<b>-4%</b>
Other income	24	28	-15%
<b>TOTAL REVENUE</b>	<b>1,490</b>	<b>1,557</b>	<b>-4%</b>
<b>EXPENDITURE</b>			
Material & Power costs	491	549	-10%
Staff costs	309	293	6%
Research & Development expenses*	79	92	-15%
Other expenses	149	193	-22%
<b>Manufacturing, staff &amp; other expenses</b>	<b>1,028</b>	<b>1,126</b>	<b>-9%</b>
<b>EBITDA</b>	<b>462</b>	<b>431</b>	<b>7%</b>
Interest & Finance charges	17	16	4%
Depreciation & Amortisation	124	120	4%
Share of profit in JV / Associate, net	8	11	-29%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>313</b>	<b>284</b>	<b>10%</b>
Exceptional item, Net	-	-	-
<b>PBT</b>	<b>313</b>	<b>284</b>	<b>10%</b>
Taxes	69	41	68%
Taxes on exceptional item	17	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>228</b>	<b>243</b>	<b>-6%</b>
Minority interest	21	30	-28%
<b>NET PROFIT FOR THE PERIOD</b>	<b>206</b>	<b>214</b>	<b>-3%</b>
<b>EPS Rs.</b>	<b>1.7</b>	<b>1.8</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>	<b>223</b>	<b>214</b>	<b>4%</b>
Exceptional item, net of taxes	(17)	-	
<b>NET PROFIT FOR THE PERIOD</b>	<b>206</b>	<b>214</b>	<b>-3%</b>
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	7	7	
* Gross Research & Development expenses	110	166	